AIN457Q
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $885,665 | 17 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $885,665 | 17 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A TWO-YEAR, PHASE III RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY, EFFICACY, AND TOLERABILITY OF 300 MG S.C. SECUKINUMAB VERSUS PLACEBO, IN COMBINATION WITH SOC THERAPY, IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS | Novartis Pharmaceuticals Corporation | $885,545 | 0 |
| A TWO-YEAR, PHASE III RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY, EFFICACY, AND TOLERABILITY OF 300 MG S.C. SECUKINUMAB VERSUS PLACEBO, IN COMBINATION WITH SOC THERAPY, IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS | NOVARTIS PHARMACEUTICALS CORPORATION | $120.00 | 0 |
Top Doctors Receiving Payments for AIN457Q
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Amarillo, TX | $885,665 | 17 |
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $885,545
- NOVARTIS PHARMACEUTICALS CORPORATION $120.00
Product Information
- Type Biological
- Total Payments $885,665
- Total Doctors 0
- Transactions 17
About AIN457Q
AIN457Q is a biological associated with $885,665 in payments to 0 healthcare providers, recorded across 17 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $885,665 was paid across 17 transactions to 0 doctors.
The most common payment nature for AIN457Q is "Unspecified" ($885,665, 100.0% of total).
AIN457Q is associated with 2 research studies, including "A TWO-YEAR, PHASE III RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY, EFFICACY, AND TOLERABILITY OF 300 MG S.C. SECUKINUMAB VERSUS PLACEBO, IN COMBINATION WITH SOC THERAPY, IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS" ($885,545).